Immune Escape Mechanisms in Diffuse Large B-Cell Lymphoma
Authors:
Open Access
- 23 December 2012
- journal article
- Published by Hindawi Limited in ISRN Immunology
- Vol. 2012, 1-6
Abstract
Diffuse large B-cell lymphoma (DLBCL) is the most frequent subtype of non-Hodgkin lymphomas in Western countries. Implementation of immunotherapy using monoclonal antibodies to therapeutic protocols has led to dramatic improvements in overall survival. DLBCL became a model of a successful immunochemotherapy concept. Despite this fact, there is still a proportion of patients who do not respond to or relapse early after treatment. Growing evidence suggests that host antitumor immunity is suppressed by lymphoma cells in many ways. First, host cytotoxic T cells are directly suppressed by interaction with programmed cell death (PD) ligand on lymphoma cell surface and a similar mechanism enhances the activity of suppressive regulatory T cells (Tregs). Second, tumor cells escape host cytotoxic cells due to lower immunogenicity caused by reduced expression of HLA antigens. Both mechanisms have an origin in primary genetic events in lymphomagenesis. Rearrangement of MHC class II transcriptional activator (CIITA) gene and amplification of Janus kinase (JAK2) gene lead to enhanced expression of PD ligands 1 and 2, higher proliferation activity, and lower expression of HLA. This paper summarizes current knowledge about clinically relevant immune escape mechanisms in DLBCL.Keywords
Funding Information
- Czech Ministry of Health’s Departmental Research and Development (IGA NT 11103, MSM 6198959205, LF-2012-007)
This publication has 35 references indexed in Scilit:
- Ten-Year Relative Survival and Causes of Death in Elderly Patients Treated With R-CHOP or CHOP in the GELA LNH-985 TrialClinical Lymphoma Myeloma and Leukemia, 2012
- Programmed Death Ligand 2 in Cancer-Induced Immune SuppressionJournal of Immunology Research, 2012
- Lymphopenia following the completion of first-line therapy predicts early relapse in patients with diffuse large B cell lymphomaAnnals of Hematology, 2011
- Chemotherapy rescues tumor-driven aberrant CD4+ T-cell differentiation and restores an activated polyfunctional helper phenotypeBlood, 2010
- RITUXIMAB DOES NOT ADVERSELY AFFECT THE STEM CELL MOBILIZATION AND ENGRAFTMENT AFTER HIGH-DOSE THERAPY AND AUTOLOGOUS TRANSPLANTATION IN PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA IN FIRST COMPLETE OR PARTIAL REMISSIONBiomedical Papers, 2009
- Low absolute lymphocyte count is a poor prognostic factor in diffuse-large-B-cell-lymphomaLeukemia & Lymphoma, 2008
- Lymphoma incidence patterns by WHO subtype in the United States, 1992-2001Blood, 2006
- Loss of major histocompatibility class II expression in non-immune-privileged site diffuse large B-cell lymphoma is highly coordinated and not due to chromosomal deletionsBlood, 2005
- Loss of MHC class II gene and protein expression in diffuse large B-cell lymphoma is related to decreased tumor immunosurveillance and poor patient survival regardless of other prognostic factors: a follow-up study from the Leukemia and Lymphoma Molecular Profiling ProjectBlood, 2004
- A Prognostic Score for Advanced Hodgkin's DiseaseNew England Journal of Medicine, 1998